Subscribe to RSS

DOI: 10.1055/a-2721-6552
A rural-to-center artificial intelligence model for diagnosing Helicobacter pylori infection and premalignant gastric conditions using endoscopy images captured in routine practice
Authors
Supported by: National Taiwan University Hospital 114-E0009
Supported by: National Science and Technology Council 111-2314-B-002-136-MY3 and 114-2314-B-002-245-MY3
Clinical Trial:
Registration number (trial ID): NCT05762991, Trial registry: ClinicalTrials.gov (http://www.clinicaltrials.gov/), Type of Study: Prospective

Abstract
Background
Diagnosing Helicobacter pylori infection and premalignant gastric conditions typically requires 13C urea breath testing or histological assessment, which are often unavailable in remote areas. A rural-to-center artificial intelligence (AI) model was developed and implemented to automatically evaluate upper endoscopy images from routine clinical practice.
Methods
Endoscopic images were collected from a rural hospital on Matsu Islands and a tertiary center across Taiwan Strait. During model development (2020–2022), AI algorithms were trained, validated, and tested to exclude low-quality and non-gastric images, segment gastric regions, and enhance mucosal features for detecting H. pylori infection and premalignant conditions. During model implementation (2023–2024), endoscopic images from a rural hospital were transmitted to the medical center for AI analyses, with results promptly returned.
Results
In the development phase, diagnostic accuracies were 92.8% (95%CI 88.9%–96.6%) for H. pylori, 88.6% (95%CI 87.2%–90.0%) for atrophic gastritis, and 88.0% (95%CI 86.5%–89.5%) for intestinal metaplasia. In the implementation phase, 3518 rural residents underwent 13C urea breath testing or pepsinogen testing; 421 with positive results underwent endoscopy. No significant differences were observed between AI-predicted and clinically observed prevalence: H. pylori (13.9% vs. 12.9%; P = 0.55), atrophic gastritis (15.7% vs. 11.9%; P = 0.34), and intestinal metaplasia (27.6% vs. 22.4%; P = 0.32). Implementation-phase diagnostic accuracies were 91.3% (95%CI 88.0%–94.6%), 79.9% (95%CI 72.1%–86.3%), and 63.4% (95%CI 54.7%–71.6%), respectively.
Conclusions
AI enabled physicians in resource-limited settings to rapidly assess gastric health using routinely captured endoscopic images, bridging gaps in access and expertise.
Publication History
Received: 23 May 2025
Accepted after revision: 12 October 2025
Accepted Manuscript online:
13 October 2025
Article published online:
26 November 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Accessed December 31, 2024 at: https://gco.iarc.who.int/today
- 2 Ford AC, Yuan Y, Park JY. et al. Eradication therapy to prevent gastric cancer in H. pylori-positive individuals: systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology 2025; 169: 261-276
- 3 Park JY. Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: guidance on implementation. Lyon, France: International Agency for Research on Cancer; 2025. Accessed April 28, 2025 at: https://publications.iarc.who.int/648
- 4 Lee YC, Chiang TH, Chiu HM. et al. Collaborators of Taiwan Community-based Integrated Screening Group. Screening for Helicobacter pylori to prevent gastric cancer: a pragmatic randomized clinical trial. JAMA 2024; 332: 1642-1651
- 5 Dinis-Ribeiro M, Shah S, El-Serag H. et al. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines. Gut 2024; 73: 1607–1617. Erratum in: Gut 2024; 73: e1
- 6 Huang RJ, Laszkowska M, In H. et al. Controlling gastric cancer in a world of heterogeneous risk. Gastroenterology 2023; 164: 736-751
- 7 Dilaghi E, Lahner E, Annibale B. et al. Systematic review and meta-analysis: artificial intelligence for the diagnosis of gastric precancerous lesions and Helicobacter pylori infection. Dig Liver Dis 2022; 54: 1630-1638
- 8 Shi Y, Wei N, Wang K. et al. Diagnostic value of artificial intelligence-assisted endoscopy for chronic atrophic gastritis: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1134980
- 9 Li N, Yang J, Li X. et al. Accuracy of artificial intelligence-assisted endoscopy in the diagnosis of gastric intestinal metaplasia: a systematic review and meta-analysis. PLoS One 2024; 19: e0303421
- 10 Jiang Y, Yan H, Cui J. et al. Artificial intelligence in endoscopy for predicting Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2025; 30: e70026
- 11 Lee YC, Chen TH, Chiu HM. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676-682
- 12 Chiang TH, Chang WJ, Chen SL. et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut 2021; 70: 243-250
- 13 Lei WY, Lee JY, Chuang SL. et al. Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. Gut 2023; 72: 2231-2240
- 14 Lee YC. Population-based Helicobacter pylori screen-and-treat strategy to prevent gastric cancer in the Matsu Islands. In: Park JY. , ed. Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: guidance on implementation (IARC Working Group Reports No. 12). Lyon, France: International Agency for Research on Cancer; 2025. Accessed April 28, 2025 at: https://publications.iarc.who.int/648
- 15 Chiang TH, Maeda M, Yamada H. et al. Risk stratification for gastric cancer after Helicobacter pylori eradication: a population-based study on Matsu Islands. J Gastroenterol Hepatol 2021; 36: 671-679
- 16 Antonelli G, Libanio D, De Groof AJ. et al. QUAIDE – quality assessment of AI preclinical studies in diagnostic endoscopy. Gut 2024; 74: 153-161
- 17 Lee YC, Chao YT, Lin PJ. et al. Quality assurance of integrative big data for medical research within a multihospital system. J Formos Med Assoc 2022; 121: 1728-1738
- 18 Veitch AM, Uedo N, Yao K. et al. Optimizing early upper gastrointestinal cancer detection at endoscopy. Nat Rev Gastroenterol Hepatol 2015; 12: 660-667
- 19 Selvaraju RR, Cogswell M, Das A. et al. Grad-CAM: visual explanations from deep networks via gradient-based localization. Proceedings of the 2017 IEEE International Conference on Computer Vision (ICCV); 2017 Oct 22–29. Venice, Italy:
- 20 Sugimoto M, Murata M, Murakami K. et al. Characteristic endoscopic findings in Helicobacter pylori diagnosis in clinical practice. Expert Rev Gastroenterol Hepatol 2024; 18: 457-472
- 21 Liou JM, Chen CC, Chen MJ. et al. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213
- 22 Liou JM, Fang YJ, Chen CC. et al. Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016; 388: 2355-2365
- 23 Dixon MF, Genta RM, Yardley JH. et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181
- 24 Rugge M, Meggio A, Pennelli G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636
- 25 Capelle LG, de Vries AC, Haringsma J. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-1158
- 26 Zuiderveld K. Contrast limited adaptive histogram equalization. In: Heckbert PS. , ed. Graphics Gems IV. San Diego, CA: Academic Press; 1994: 474-485
- 27 Lundberg S, Lee SI. A unified approach to interpreting model predictions. arXiv 2017;
- 28 Esposito G, Pimentel-Nunes P, Angeletti S. et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy 2019; 51: 515-521
- 29 Almeida E, Martins ML, Marques D. et al. Artificial intelligence for endoscopic grading of gastric intestinal metaplasia: advancing risk stratification for gastric cancer. Endoscopy 2025;
- 30 Wu L, He X, Liu M. et al. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial. Endoscopy 2021; 53: 1199-1207
- 31 Siripoppohn V, Pittayanon R, Tiankanon K. et al. Real-time semantic segmentation of gastric intestinal metaplasia using a deep learning approach. Clin Endosc 2022; 55: 390-400
- 32 Pornvoraphat P, Tiankanon K, Pittayanon R. et al. Real-time gastric intestinal metaplasia diagnosis tailored for bias and noisy-labeled data with multiple endoscopic imaging. Comput Biol Med 2023; 154: 106582
- 33 Gong EJ, Bang CS, Lee JJ. et al. Deep learning-based clinical decision support system for gastric neoplasms in real-time endoscopy: development and validation study. Endoscopy 2023; 55: 701-708
- 34 Dinis-Ribeiro M, Libânio D, Uchima H. et al. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy 2025; 57: 504-554
- 35 Morgan DR, Corral JE, Li D. et al. ACG Clinical Guideline: Diagnosis and management of gastric premalignant conditions. Am J Gastroenterol 2025; 120: 709-737
